Fetal Medicine Unit, St George's University Hospital, London, UK
Fetal Medicine Unit, Liverpool Women's Hospital, University of Liverpool, Liverpool, UK.
BMJ Open. 2024 Aug 17;14(8):e080021. doi: 10.1136/bmjopen-2023-080021.
Selective fetal growth restriction (sFGR) in monochorionic twin pregnancy, defined as an estimated fetal weight (EFW) of one twin <10th centile and EFW discordance ≥25%, is associated with stillbirth and neurodisability for both twins. The condition poses unique management difficulties: on the one hand, continuation of the pregnancy carries a risk of death of the smaller twin, with a high risk of co-twin demise (40%) or co-twin neurological sequelae (30%). On the other, early delivery to prevent the death of the smaller twin may expose the larger twin to prematurity, with the associated risks of long-term physical, emotional and financial costs from neurodisability, such as cerebral palsy.When there is severe and early sFGR, before viability, delivery is not an option. In this scenario, there are currently three main management options: (1) expectant management, (2) selective termination of the smaller twin and (3) placental laser photocoagulation of interconnecting vessels. These management options have never been investigated in a randomised controlled trial (RCT). The best management option is unknown, and there are many challenges for a potential RCT. These include the rarity of the condition resulting in a small number of eligible pregnancies, uncertainty about whether pregnant women will agree to participate in such a trial and whether they will agree to be randomised to expectant management or active fetal intervention, and the challenges of robust and long-term outcome measures. Therefore, the main objective of the FERN study is to assess the feasibility of conducting an RCT of active intervention vs expectant management in monochorionic twin pregnancies with early-onset (prior to 24 weeks) sFGR.
The FERN study is a prospective mixed-methods feasibility study. The primary objective is to recommend whether an RCT of intervention vs expectant management of sFGR in monochorionic twin pregnancy is feasible by exploring women's preference, clinician's preference, current practice and equipoise and numbers of cases. To achieve this, we propose three distinct work packages (WPs). WP1: A Prospective UK Multicentre Study, WP2A: a Qualitative Study Exploring Parents' and Clinicians' Views and WP3: a Consensus Development to Determine Feasibility of a Trial. Eligible pregnancies will be recruited to WP1 and WP2, which will run concurrently. The results of these two WPs will be used in WP3 to develop consensus on a future definitive study. The duration of the study will be 53 months, composed of 10 months of setup, 39 months of recruitment, 42 months of data collection, and 5 months of data analysis, report writing and recommendations. The pragmatic sample size for WP1 is 100 monochorionic twin pregnancies with sFGR. For WP2, interviews will be conducted until data saturation and sample variance are achieved, that is, when no new major themes are being discovered. Based on previous similar pilot studies, this is anticipated to be approximately 15-25 interviews in both the parent and clinician groups. Engagement of at least 50 UK clinicians is planned for WP3.
This study has received ethical approval from the Health Research Authority (HRA) South West-Cornwall and Plymouth Ethics Committee (REC reference 20/SW/0156, IRAS ID 286337). All participating sites will undergo site-specific approvals for assessment of capacity and capability by the HRA. The results of this study will be published in peer-reviewed journals and presented at national and international conferences. The results from the FERN project will be used to inform future studies.
This study is included in the ISRCTN Registry (ISRCTN16879394) and the NIHR Central Portfolio Management System (CPMS), CRN: Reproductive Health and Childbirth Specialty (UKCRN reference 47201).
在单绒毛膜双胞胎妊娠中,选择性胎儿生长受限(sFGR)定义为一个胎儿的估计胎儿体重(EFW)小于第 10 百分位数,且 EFW 差异≥25%,与两个胎儿的死产和神经发育障碍有关。这种情况带来了独特的管理难题:一方面,继续妊娠会使较小的胎儿死亡的风险增加,双胎之一死亡的风险(40%)或双胎之一神经后遗症的风险(30%)较高。另一方面,为了防止较小的胎儿死亡而提前分娩可能会使较大的胎儿面临早产的风险,早产儿可能会出现长期的身体、情感和经济方面的残疾,如脑瘫。当存在严重且早期的 sFGR 时,在可存活之前,分娩不是一个选择。在这种情况下,目前有三种主要的管理选择:(1)期待管理,(2)选择性终止较小的胎儿,(3)胎盘连通血管激光光凝。这些管理选择从未在随机对照试验(RCT)中进行过研究。最佳管理选择尚不清楚,并且对于潜在的 RCT 存在许多挑战。这些挑战包括这种情况的罕见性导致符合条件的妊娠数量较少,孕妇是否同意参与此类试验以及是否同意接受期待管理或胎儿积极干预的随机分组存在不确定性,以及稳健和长期结果测量的挑战。因此,FERN 研究的主要目标是评估在早发(24 周之前)sFGR 的单绒毛膜双胞胎妊娠中进行积极干预与期待管理的 RCT 的可行性。
FERN 研究是一项前瞻性混合方法可行性研究。主要目的是通过探讨女性的偏好、临床医生的偏好、当前的实践和平衡以及病例数量,来推荐在单绒毛膜双胞胎妊娠中 sFGR 的干预与期待管理的 RCT 是否可行。为此,我们提出了三个不同的工作包(WP)。WP1:一项英国多中心前瞻性研究,WP2A:一项探索父母和临床医生观点的定性研究,WP3:一项确定试验可行性的共识发展。符合条件的妊娠将被招募到 WP1 和 WP2,这两个 WP 将同时进行。这两个 WP 的结果将用于 WP3 来就未来的确定性研究达成共识。该研究的持续时间为 53 个月,由 10 个月的筹备阶段、39 个月的招募阶段、42 个月的数据收集阶段和 5 个月的数据分析、报告撰写和建议阶段组成。WP1 的实用样本量为 100 例 sFGR 的单绒毛膜双胞胎妊娠。对于 WP2,访谈将持续进行,直到达到数据饱和和样本方差,即当没有新的主要主题被发现时。根据之前的类似试点研究,预计在父母和临床医生两组中各进行约 15-25 次访谈。计划 WP3 有至少 50 名英国临床医生参与。
这项研究已获得英国南威尔士-康沃尔和普利茅斯伦理委员会的伦理批准(REC 参考号 20/SW/0156,IRAS ID 286337)。所有参与的地点都将经过 HRA 的特定地点批准,以评估其能力和能力。这项研究的结果将在同行评议的期刊上发表,并在国内和国际会议上展示。FERN 项目的结果将用于指导未来的研究。
这项研究被列入 ISRCTN 注册表(ISRCTN85352305)和英国国家健康研究所中央组合管理系统(CPMS),CRN:生殖健康和分娩专业(英国 CRN 参考号 47201)。